NovoCure/$NVCR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NovoCure
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Ticker
$NVCR
Sector
Primary listing
Employees
1,488
Headquarters
Baar, Switzerland
Website
NovoCure Metrics
BasicAdvanced
$1.4B
-
-$1.56
0.72
-
Price and volume
Market cap
$1.4B
Beta
0.72
52-week high
$34.13
52-week low
$10.87
Average daily volume
1.6M
Financial strength
Current ratio
1.445
Quick ratio
1.388
Long term debt to equity
40.196
Total debt to equity
200.392
Interest coverage (TTM)
-12.27%
Profitability
EBITDA (TTM)
-158.863
Gross margin (TTM)
76.54%
Net profit margin (TTM)
-27.13%
Operating margin (TTM)
-26.95%
Effective tax rate (TTM)
-20.33%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-8.64%
Return on equity (TTM)
-48.07%
Valuation
Price to revenue (TTM)
2.213
Price to book
4.07
Price to tangible book (TTM)
4.07
Price to free cash flow (TTM)
-17.347
Free cash flow yield (TTM)
-5.76%
Free cash flow per share (TTM)
-0.734
Growth
Revenue change (TTM)
14.58%
Earnings per share change (TTM)
-1.15%
3-year revenue growth (CAGR)
4.94%
10-year revenue growth (CAGR)
41.25%
3-year earnings per share growth (CAGR)
33.52%
10-year earnings per share growth (CAGR)
-14.37%
What the Analysts think about NovoCure
Analyst ratings (Buy, Hold, Sell) for NovoCure stock.
Bulls say / Bears say
The Phase 3 PANOVA-3 trial in locally advanced pancreatic cancer met its primary endpoint with a statistically significant 2.0-month median overall survival improvement (16.2 vs. 14.2 months), paving the way for a PMA application to the FDA and potential multi-market approvals (Nasdaq).
Optune Gio active patient count grew 7% year-over-year to 4,194 as of June 30 2025, reflecting sustained commercial momentum in glioblastoma treatment across key markets (Nasdaq).
NovoCure ended Q2 2025 with $911.5 million in cash, cash equivalents and short-term investments, providing a strong financial runway to fund ongoing clinical trials and product launches (Nasdaq).
Gross margin declined to 74% in Q2 2025 from 77% year-over-year, driven by higher production costs associated with the new Head Flexible Electrode rollout, upfront NSCLC launch costs ahead of broad reimbursement, and rising tariffs (Nasdaq).
NovoCure reported a net loss of $40.1 million in Q2 2025, or a loss per share of $0.36, underscoring continued unprofitability despite revenue growth (GuruFocus).
Optune Lua adoption remains modest, with only 137 active patients globally as of June 30 2025, indicating early traction in the NSCLC and MPM markets has been limited (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
NovoCure Financial Performance
Revenues and expenses
NovoCure Earnings Performance
Company profitability
NovoCure News
AllArticlesVideos
Novocure Announces Upcoming Investor Events
Business Wire2 weeks ago
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
Business Wire3 weeks ago
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NovoCure stock?
NovoCure (NVCR) has a market cap of $1.4B as of September 13, 2025.
What is the P/E ratio for NovoCure stock?
The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of September 13, 2025.
Does NovoCure stock pay dividends?
No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next NovoCure dividend payment date?
NovoCure (NVCR) stock does not pay dividends to its shareholders.
What is the beta indicator for NovoCure?
NovoCure (NVCR) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.